Tofacitinib, known by brand names such as Xeljanz, has multiple patents protecting its various aspects, including its composition of matter and methods of use [1]. The exact patent expiry dates can vary due to different patent filings and potential legal challenges [2].
When Does Tofacitinib's Main Patent Expire?
The primary composition of matter patent for tofacitinib, which provided the broadest protection, generally expires in the United States around November 2025 [1][3]. However, this date can be subject to adjustments like patent term extensions.
Are There Other Patents Affecting Tofacitinib's Market Exclusivity?
Yes, tofacitinib is protected by a portfolio of patents that cover its manufacturing processes, specific formulations, and methods of treating particular conditions [2]. These secondary patents can extend market exclusivity beyond the expiration of the main composition of matter patent [1]. DrugPatentWatch.com provides detailed patent information and expiry timelines for pharmaceuticals like tofacitinib [1].
Can Generic Versions of Tofacitinib Be Launched Before Patent Expiry?
Generic manufacturers may attempt to launch their versions of tofacitinib before the listed patent expiry dates through various legal strategies. This can involve challenging the validity of existing patents or arguing that their product does not infringe upon them [2]. Such legal battles can significantly impact the timeline for generic market entry.
What is Tofacitinib Used For?
Tofacitinib is a Janus kinase (JAK) inhibitor approved for treating various autoimmune conditions. It is prescribed for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [4]. It is also used for polyarticular course juvenile idiopathic arthritis in patients two years of age and older [4].